0RGI Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Cosmo Pharmaceuticals NV

Watchlist Manager

Watchlist

Price: 50.25 CHF -3.55%

Market Cap: CHf753.9m

	Cosmo Pharmaceuticals NV LSE:0RGI	IE
E	Elvila SA XBSE:ELV	RO
M	Multi Indocitra Tbk PT SWB:QF9	ID

Profitability Summary

Cosmo Pharmaceuticals NV's profitability score is 40/100. We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Healthy Gross Margin

46%

Strong 3Y Average Gross Margin

64%

Declining Gross Margin

60% > 46%

Negative Operating Margin

-8%

Sustainable 3Y Average Operating Margin

19%

Declining Operating Margin

26% > -8%

Negative Net Margin

-6%

Sustainable 3Y Average Net Margin

15%

Declining Net Margin

10% > -6%

Negative Free Cash Flow Margin

-25%

Strong 3Y Average Free Cash Flow Margin

21%

Declining Free Cash Flow Margin

View All

Hide

Collapse

40 / 100

Profitability
Score

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.